Sir John is Chairman of the Newcastle upon Tyne Hospitals NHS Foundation Trust, Professor of Clinical Genetics at Newcastle University, led the regional NHS Genetics Service for 20 years and helped to create the International Centre for Life.

Jonathan is the co-founder of QuantuMDx, former Chief Scientific Officer and inventor of many of its proprietary technologies. Jonathan has a specialist interest in antimicrobial resistance (AMR) and was a diagnostics advisor for the O’Neill Review. He was awarded European CTO of the Year in 2015.

James is the managing partner and co-founder of Vita Spring IVD Fund, who participated as the institutional investor, and support the management team in fund raising and strategic development. Prior to his investment career, he worked as an investment banker for seven years and was an Executive Director in Goldman Sachs.

Martin has over 25 years’ experience of working with large global companies. He previously set up and managed Excalibur Medicines Ltd, he sits on the Board of Interrad Medical and is a Partnership Board Member of the Liverpool Life Sciences Accelerator.

Justine has been with QuantuMDx Group for almost eight years and in that time has gathered a wealth of experience of working in the life sciences sector. Justine joined as Financial Controller in 2015, and was promoted to VP Finance in 2018. In that time, Justine has developed a high-performing financial team, introduced and enhanced the managment reporting within the Company, transitioned the statutory reporting to IFRS from UK GAAP, maximised R&D tax credit subsidies to the business, managed the implementation of the ERP system and been instrumental in all of the Company's recent fund-raising activities. Justine qualified as an ACA with the "Big Four" accountancy firm, EY and left two years post-qualification. Since then, Justine has worked across financial departments in both local SMEs and large Global Companies, her most recent post prior to joining QuantuMDx was Financial Reporting Manager at FTSE 100 Company, The Sage Group plc.

Andy is a specialist in global operations and manufacturing with over 24 years' experience in the medical device and life sciences sector. During a 13-year tenure with Thermofisher, he successfully launched over 40 products in the UK and German facilities. The remaining time at Thermofisher was spent in the life sciences division leading a 24x7 manufacturing facility as site Operations Manager, with a turnover of $38M and 156 employees, outputting over 10 million PCR consumables per year. Andy led all operational activities across the site, initiated and managed the continuous improvement program, which led to his site being awarded best in class. The site expanded by 25%, establishing an ISO-13485 manufacturing facility and supplying customers such as Roche. Andy gained start-up experience with Vivacta Ltd where he was Director of Manufacturing during the lead up to the acquisition by Novartis. He then progressed to Global Head of Manufacturing Operations and during his 5-year tenure, Andy fulfilled Novartis' high standards leading and establishing in house manufacturing of Niji cassette consumables in the UK and successfully achieving ISO-13485 certification. Andy also participated in assessing potential new technology acquisitions.

Robin is a specialist in biosensor technologies with over 18 years’ experience working in academia and industry. Robin has in-depth experience of molecular biology and surface chemistry and currently leads our project management team.